Abstract
The MOXIe Trial of Omaveloxolone in Friedreich Ataxia: Exploring the Transient Nature of Treatment-emergent Adverse Events (P7-3.016)
Neurology, Vol.102(17_supplement_1)
04/09/2024
DOI: 10.1212/WNL.0000000000205176
Abstract
Abstract only
Details
- Title: Subtitle
- The MOXIe Trial of Omaveloxolone in Friedreich Ataxia: Exploring the Transient Nature of Treatment-emergent Adverse Events (P7-3.016)
- Creators
- David Lynch - Children's Hospital of PhiladelphiaSylvia Boesch - Innsbruck Medical UniversityMartin Delatycki - Murdoch Children's Research InstitutePaola Giunti - University College HospitalAngie Goldsberry - Reata Pharmaceuticals (United States)Chad Hoyle - The Ohio State UniversityKatherine Mathews - University of IowaSeemi Khan - Reata Pharmaceuticals (United States)Colin Meyer - Reata Pharmaceuticals (United States)Masako Murai - Reata Pharmaceuticals (United States)Wolfgang Nachbauer - Innsbruck Medical UniversitySusan Perlman - University of California, Los AngelesS Subramony - University of Florida HealthTheresa Zesiewicz - University of South Florida
- Resource Type
- Abstract
- Publication Details
- Neurology, Vol.102(17_supplement_1)
- DOI
- 10.1212/WNL.0000000000205176
- ISSN
- 0028-3878
- eISSN
- 1526-632X
- Language
- English
- Date published
- 04/09/2024
- Academic Unit
- Neurology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Neurology (Pediatrics)
- Record Identifier
- 9984643649202771
Metrics
101 Record Views